A retrospective single-center cohort of 128 patients associated frontline bevacizumab with longer overall survival in ...

Corcept Therapeutics Incorporated CORT on Monday released positive findings from Part A of its Phase 2 BELLA clinical trial, ...

A real-world study based on information from an electronic health records–derived database reveals limited benefits of adding bevacizumab to first-line chemotherapy for patients with ovarian cancer, ...

Compared with chemotherapy alone, 1L chemotherapy plus bevacizumab was associated with a trend toward longer median real-world overall survival. HealthDay News — The addition of bevacizumab to ...

The Phase 1 study by Lilly assessed Sofe-M plus bevacizumab in 33 women with platinum-sensitive ovarian cancer (PSOC).

Corcept Therapeutics Incorporated announced positive results from Part A of the company?s Phase 2 BELLA trial, which evaluated Lifyorli in combination with nab-paclitaxel and bevacizumab in 95 ...

Ovarian cancer comprises a group of different cancers that can form in the ovaries, fallopian tubes, or the peritoneum. For those patients within this population with aggressive disease, continuous ...

National Institute for Health and Care Excellence (NICE) has recommended Lonsurf (trifluridine–tipiracil, Servier Laboratories) plus bevacizumab in final draft guidance for treating metastatic ...

ORLANDO, Florida (Reuters) - A study of blockbuster drug Avastin in colon cancer patients who have undergone surgery showed that the drug's effectiveness wore off after patients stopped taking it, ...

November 18, 2011 — The US Food and Drug Administration (FDA) announced today that it is rescinding its approval of bevacizumab (Avastin, Genentech) for treating metastatic breast cancer because the ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic ...